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Plasmodium falciparum Choline  
Kinase Inhibition Leads 
to a Major Decrease in 
Phosphatidylethanolamine  
Causing Parasite Death
Lucía Serrán-Aguilera1,*, Helen Denton2,*, Belén Rubio-Ruiz1,†, Borja López-Gutiérrez3, 
Antonio Entrena1, Luis Izquierdo3, Terry K. Smith2, Ana Conejo-García1,4 & Ramon Hurtado-
Guerrero5,6
Malaria is a life-threatening disease caused by different species of the protozoan parasite Plasmodium, 
with P. falciparum being the deadliest. Increasing parasitic resistance to existing antimalarials makes 
the necessity of novel avenues to treat this disease an urgent priority. The enzymes responsible for the 
synthesis of phosphatidylcholine and phosphatidylethanolamine are attractive drug targets to treat 
malaria as their selective inhibition leads to an arrest of the parasite’s growth and cures malaria in a 
mouse model. We present here a detailed study that reveals a mode of action for two P. falciparum 
choline kinase inhibitors both in vitro and in vivo. The compounds present distinct binding modes to 
the choline/ethanolamine-binding site of P. falciparum choline kinase, reflecting different types of 
inhibition. Strikingly, these compounds primarily inhibit the ethanolamine kinase activity of the  
P. falciparum choline kinase, leading to a severe decrease in the phosphatidylethanolamine levels within 
P. falciparum, which explains the resulting growth phenotype and the parasites death. These studies 
provide an understanding of the mode of action, and act as a springboard for continued antimalarial 
development efforts selectively targeting P. falciparum choline kinase.
Malaria remains an important global health concern. According to the latest estimates, 214 million cases of 
malaria occurred globally in 2014 and approximately half million deaths, primarily children aged under 5 year, 
in Africa1. Malaria is caused by various Plasmodium parasites. Of these, P. vivax, P. malariae, P. ovale and 
P. falciparum cause malaria in humans with the latter being one of the most common and the most deadly. In 
recent years, P. knowlesi has also been reported to infect humans in certain forested areas of South-East Asia2. A 
major obstacle to the eradication of this disease is the emerging resistance of Plasmodium parasites to most mar-
keted antimalarial drugs3–5. There is therefore an urgent need for new antimalarial agents acting through novel 
mechanisms of action.
Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) are major and essential phospholipids in 
P. falciparum membranes. Their content is unusually high representing 40–50% and 35–40% of the total phos-
pholipids in P. falciparum, respectively6,7. Thus, the pathways leading to their synthesis are attractive targets for 
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malaria chemotherapy8–11. PC and PE are mainly synthesized in P. falciparum by the Kennedy pathways from 
choline (Cho) or ethanolamine (Etn)12. The synthesis is initiated by phosphorylation of Cho and Etn to render 
phosphocholine (PCho) and phosphoethanolamine (PEtn) by choline kinase (CK) and ethanolamine kinase (EK) 
respectively. However, in many organisms one or other or both of these kinases are able to phosphorylate both 
substrates to varying degrees12. PCho and PEtn are in turn converted to CDP-choline and CDP-ethanolamine by 
the choline-phosphate cytidyltransferase (CCT) and ethanolamine-phosphate cytidyltransferase (ECT), respec-
tively. Finally, PC and PE are synthesized via a common choline/ethanolamine phosphotransferase (CEPT). In 
addition, P. falciparum possesses an alternative route for the synthesis of PC from Etn that involves the methyla-
tion of PEtn by a phosphoethanolamine N-methyltransferase (PMT) to form PCho which subsequently form PC, 
thus connecting both Kennedy pathways6,13.
We have previously focused on the Cho phospholipid metabolism in cancer cells and tumors as a therapeutic 
target by inhibiting the human CK activity. In humans, CK is encoded by two genes, which express three iso-
forms CKα 1, CKα 2 and CKβ . An overexpression of the α -isoform of CK has been identified as an oncogene that 
mediates human cell transformation. As a consequence, CKα has been proposed and validated as a molecular 
target for the development of novel cancer therapeutic agents14,15. We rationally designed several CKα inhibitors 
initially based on structural modifications of the Cho uptake inhibitor Hemicholinium-3 and in the crystal struc-
ture of human CKα 2 isoform subsequently16–22. Our earlier results showed one compound (BR7, Figure S1) that 
was uniquely able to occupy both Cho and ATP binding sites simultaneously20 whereas the rest of the inhibitors 
exclusively bound to the Cho-binding site21,22. We have also shown recently that compound BR33 (Figure S1) was 
able to induce local conformational changes in the Cho-binding site, which induced the aperture of an adjacent 
binding site22.
Considering their inhibition properties in the human CKα 1 (HsCKα 1) and the high identity between the 
human CKα 1 and the P. falciparum CK (PfCK) at the binding site (29% identity between HsCKα 1 and PfCK 
that increases up to ~69% when only conserved residues of ATP and Cho binding sites are considered (ref. 23; 
Figure S2), we rationalized that these compounds might also inhibit PfCK, and therefore the growth of P. falci-
parum parasites. Thus, we recently evaluated the in vitro antiplasmodial and cytotoxic effects of some of these 
inhibitors against P. falciparum24. The compounds were found to be lethal for the blood stages of the parasite 
in a dose-dependent manner with IC50 values in the low nM range. The two most active compounds, BR23 and 
BR25 (Figure S1), with IC50 of 3 and 2 nM respectively24, were selected to further investigate their mode of action 
against P. falciparum.
Herein, we present a study on the mechanism of action of BR23 and BR25 both in vitro and in vivo. BR23 and 
BR25 lead to a severe drastic decrease of the PE pools in vivo that might explain the potent antiplasmodial and 
highly selective effect shown previously24. Contrary to what could be expected from the in vivo results, the com-
pounds do not inhibit the PfEK but the PfCK. Surprisingly, our data reveals that these compounds have slightly 
different types of inhibition and majorly inhibit the EK activity of PfCK. Finally, both compounds present two 
different binding modes in the Cho-binding site of PfCK compared to the human enzyme.
Results
BR23 and BR25 lead to a dramatic decrease of the parasite PE pool. As it was highly likely that 
treatment of either BR23 or BR25 to the whole parasite could affect phospholipid biosynthesis, namely the synthe-
sis of PC and PE, we performed lipidomic analysis of parasites treated with the compounds and compared these 
to untreated. The positive-ion survey scan of the untreated cells revealed the expected array of PC species, which 
were unchanged in the lipid extracts of the cells treated with either BR23 or BR25 (Figure S3). The corresponding 
negative ion survey spectrum of the untreated cells showed the expected mixture of PE, phosphatidylserine PS, 
phosphatidylinositol (PI) and phosphatidylglycerol (PG) species (Fig. 1A) as previously described25. However, 
upon treatment with BR23, the relative amount of the lipid species at 715 and 717 m/z were decreased compared 
to the other phospholipids (black arrows within Fig. 1B). ES-MS-MS daughter ion fragmentation of these lipid 
species (Figure S4) revealed that they correspond to PE (34:1 and 34:2). The reduction in the PE species was more 
pronounced in the cells treated with BR25 at EC90 (black arrows within Fig. 1C), compared to the wild type after 
3h treatment.
In order to confirm these observations and to quantify the reduction in PE species levels, new samples were 
treated at EC90 for 3 h with the inclusion of internal standard of PE and PC. Upon ES-MS-MS analysis looking at 
parents 196 m/z, which shows only the PE species (Fig. 1D–F), untreated cells showed the internal PE standard 
species (692 m/z), and other endogenous PE species at 715–719 m/z (34:0–2), 743–5 m/z (36:1–2) and 775 m/z 
(38:1) (Figure S4 and data not shown). Upon treatment with BR23, all of these endogenous PE species are greatly 
reduced (> 90%), while the BR25 treated cells show an almost complete loss of all of the endogenous PE species 
(compare black arrows within Fig. 1E,F with control 1D). In contrast, treatments of BR23 or BR25 do not affect 
the level of PC species as determined by the parents of 184 m/z spectra (data not shown). We conclude that our 
compounds lead to a major decrease of the PE species without drastically affecting the PC species in the parasite.
P. falciparum trophozoites are highly susceptible to the effect of both inhibitors. Prompted 
by the above results, we analyzed the global phenotypic effect of the massive reduction of the PE species in the 
parasite. Treatment of tightly synchronized ring stage parasites (6–12 hours post invasion) with EC90 concentra-
tions of BR23 and BR25, lead to an arrest of parasite development. Rings seemed refractory to BR23 and BR25 
inhibitory effects, whereas young trophozoites were highly susceptible (Fig. 2), in agreement with the increase of 
PE biosynthesis by the parasite in the second half of its asexual life cycle26. Arrested trophozoites did not progress 
into mature segmenting schizonts. Thus, a plausible explanation of the above experiments will involve the stalled 
trophozoites may be requiring PE for membrane biogenesis as well as for glycosylphosphatidylinositol (GPI) 
biosynthesis for numerous GPI-anchored proteins known to be essential at a schizont stage11,27.
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PfCK determines the synthesis of all PCho and probably the majority of PEtn. To understand the 
molecular basis of the massive reduction in PE species, we rationalized that either the inhibition of PfCK or PfEK 
might explain the resulting phenotype induced by these compounds. While we selected PfCK due to the previous 
demonstration that these compounds inhibited the human enzyme22, PfEK was also taken into account because of 
the PE reduction-associated phenotype found in P. falciparum. At the ATP and Cho-binding sites, the similarities 
in sequence between both enzymes were high (26% identity between PfCK and PfEK that increases up to ~62% 
when only conserved residues of ATP and Cho-binding sites are considered; Figure S2), which are in agreement 
with their very similar catalyzed reactions. Hence, we inferred that either PfCK or PfEK enzymes might be drug 
targets for these compounds.
Then, we conducted the determination of the kinetic parameters of the HsCKα 1, PfCK and PfEK enzymes 
(see Methods). Note that HsCKα 1 was also kinetically evaluated to compare its kinetic parameters with the 
P. falciparum enzymes. As expected and in agreement with the literature18,28,29, the HsCKα 1 showed a high 
specific activity and affinity for both Cho and ATP, which were reflected by a high kcat and catalytic efficiency 
(Fig. 3A and Table 1). As with many of the kinases that initiate the Kennedy pathway, the HsCKα 1 is able to phos-
phorylate both Cho and Etn12. However, while the Km for Etn is ~20 times higher than the Km for Cho, their kcats 
are comparable (Fig. 3A and Table 1).
Corresponding kinetic analysis of the PfCK (Fig. 3B and Table 1) revealed that it was also able to phosphoryl-
ate both Cho and Etn. PfCK behaved in a very similar manner to the human enzyme in terms of Kms whereas the 
specific activity was lower for the parasite enzyme (Table 1). The latter is reflected in the catalytic efficiency, which 
is 10–20 times lower than that of the human enzyme.
On the contrary, the PfEK was specifically able to phosphorylate Etn and not Cho, and this was at a very low 
catalytic efficiency (Fig. 3C and Table 1). In fact, the PfCK is able to phosphorylate Etn ~60 times faster than the 
PfEK. Thus, depending upon the enzymes expression levels (and possibly cellular location), PfCK is likely to 
be responsible for the phosphorylation of all the Cho and the vast majority of the Etn in the parasites Kennedy 
pathway.
BR23 and BR25 inhibit EK activity of PfCK with higher efficiency than CK activity. With the nec-
essary kinetic values obtained, the inhibition of BR23 and BR25 on all three kinases was examined. Both of these 
compounds showed potent inhibition of the choline kinase activity of HsCKα 1 with IC50s of 940 and 520 nM, 
Figure 1. ES-MS and ES-MS-MS lipidomic analysis. Lipid extracts were made from P. falciparum in the 
absence (A) or presence of BR23 (B) and BR25 (C). Spectra show negative ion survey scans (600–1000 m/z). 
PE analysis by ES-MS-MS. Lipid extracts were made (spiked with the internal standard 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine, 692 m/z) from P. falciparum in the absence (D) or presence of BR23 (E) 
and BR25 (F). Spectra show ES-MS-MS parents of 196 m/z (for PE lipid species) spectra over the mass range 
(600–1000 m/z).
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respectively (S1 Table). Rather surprisingly, given the high degree of sequence similarity (Figure S2) between 
HsCKα 1 and PfCK, BR23 and BR25 only showed moderate inhibition towards PfCKs choline kinase activity (S1 
Table). However, when Etn was used as a substrate the inhibition of the kinase activity was far greater, with IC50s 
of 12 and 6 μ M for BR23 and BR25, respectively (S1 Table). On the contrary, neither BR23 nor BR25 showed any 
inhibition towards PfEK (S1 Table).
Figure 2. Microscopic effects (x1000 magnification) of BR23 and BR25 inhibitors on the asexual blood 
stages of a tightly (6 hours window) synchronized in vitro culture of Plasmodium falciparum. Negative 
control (NC) depicts representative stages of a complete intraerythrocytic cycle of P. falciparum in absence 
of inhibitors. BR23 and BR25 display the effects of the corresponding inhibitor at its EC90 concentration on 
morphology and development of the asexual blood stages. Time indicates hours post-invasion.
Figure 3. Cho and Etn saturation curves of recombinant HsCKα 1 (A), PfCK (B) and PfEK (C). ATP 
concentrations were held constant while Cho and Etn concentrations were varied as described in the Methods. 
Any ATPase activity was subtracted from the rates (PfEK only) and all points were assayed in triplicate. The 
values shown as open and closed circles are determined in the presence of Cho and Etn, respectively.
Substrate
Cho Etn ATP
Vmax  
(μmols/min/mg)*
Km  
(mM)*
kcat 
(s−1)
kcat/km 
(s−1mM)
Vmax  
(μmols/min/mg)*
Km  
(mM)*
kcat 
(s−1)
kcat/km 
(s−1mM)
Km  
(mM)*
HsCKα 1 27.5 ± 1.4 0.19 ± 0.04 24 127 40.3 ± 2.6 3.8 ± 0.4 36 9.4 0.32 ± 0.05
PfCK 3.3 ± 0.1 0.21 ± 0.03 2.9 13.8 1.7 ± 0.09 3.3 ± 0.3 1.5 0.45 0.13 ± 0.01
PfEK n.d. n.d. n.d. n.d. 0.03 ± 0.002 0.08 ± 0.02 0.025 0.31 0.07 ± 0.03
Table 1.  Kinetic values for recombinant HsCKα1, PfCK and PfEK. *Mean ± standard deviation (n = 3), n.d., 
not detected.
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To further probe and understand the type of inhibition caused by BR23 and BR25 on HsCKα 1 and PfCK, 
a series of kinetic analyses were undertaken to determine Ki values (S5–9 Figs). For HsCKα 1, BR23 and BR25 
were shown to have mixed inhibition with respect to ATP, with Kis ~ 4 uM, and mixed inhibition with respect 
to Cho with potent Kis ~100 nM (Table 2). The calculated high alpha factors associated with the Kis against Cho, 
suggests that both BR23 and BR25 prevent binding of the substrate (Cho/Etn) and inhibition tends towards being 
competitive. For PfCK, BR23 and BR25 also showed mixed inhibition against Cho with Kis ~35 uM, but in this 
case alpha factors were lower than for the human enzyme implying less impact on substrate binding. In contrast, 
both inhibitors were found to be competitive inhibitors of PfCK with respect to Etn with Kis of ~4 uM (Table 2). 
This implies that the absolute binding positions of the two alternative substrates (Cho and Etn) must be different 
within the active site, leading to a different inhibition profile in presence of the inhibitors.
Collectively, this data clearly shows that both compounds behave differently depending upon the enzyme and 
substrate identity, thus causing a more potent inhibition of PfCK when Etn is a substrate.
BR23 and BR25 adopt different binding modes in PfCK. To evaluate the affinity of BR23 and BR25 
on HsCKα 1 and PfCK, we determined the Kds by tryptophan fluorescence spectroscopy (Figure S10). Both com-
pounds showed Kds in the low μ M range with BR25 being 3-fold more potent in terms of affinity than BR23 for 
PfCK (Kds for BR23 and BR25 were 1,400 ± 423 and 415 ± 81 nM, respectively). These values were also compa-
rable to the obtained for the HsCKα 1 (Kds for BR23 and BR25 were 521 ± 200 and 352 ± 20 nM, respectively), in 
agreement with the high similarities inferred at the protein sequence level for both enzymes (Figure S2 and S2 Table).
Prompted by the high binding affinities of BR23 and BR25, we decided to crystallize PfCK in complex with 
both compounds to understand the molecular basis of how this enzyme recognizes these compounds. Despite 
of setting up a large number of crystallization trials, we were unable to obtain any crystals of PfCK either apo- or 
in complex with either of the compounds. Knowing the high sequence similarity between PfCK and HsCKα 1, 
we tried the alternative strategy to crystallize HsCKα 1 in complex with these compounds in order to understand 
their binding mode. Only crystals of HsCKα 1 in complex with compound BR25 were obtained that enabled us 
to solve the structure and unambiguously interpret the electron density maps (S3 Table). As expected, the crystal 
structure shows that BR25 is located within the known Cho-binding site (Fig. 4A). Strikingly the compound 
favors the unusual conformation also found for BR33 in which a new adjacent binding site is formed that is 
located at the back of the Cho-binding site (Fig. 4B)22.
Contrary to BR25, BR23 was computationally predicted to be located in the Cho-binding site of HsCKα 1 
and adopt the typical binding mode, which is also visualized for most of the compounds previously crystallized 
such as BR31 (Fig. 4C,D; see Methods)21,22. Whereas compounds adopting the typical binding mode contain a 
short and rigid linker consisting of a biphenyl group, BR25 and BR33 have the flexible linker 1,4-biphenylbutane, 
explaining why the latter compounds adopt the unusual binding mode in which the aperture of an adjacent bind-
ing site is induced.
Compound BR25, in contrast to compound BR23, induces local conformational changes of several amino 
acids, allowing the 4-(dimethylamino)pyridinium fragment to access the adjacent binding site (Figs 4A and S11). 
This is mainly evidenced by W420 in which a dramatic conformational change occurs (Fig. 4A,C). W420 has 
to rotate < 57.1° (the typical orientation of W420 found in most crystal structures is compared with the same 
amino acid from the complex with compound BR23) for the above fragment to access the hydrophobic pocket 
located in this adjacent binding site (Fig. 4A), which is formed by W248, Y256, Y333, L419, W420, and W423. 
The rest of BR25 is located in the Cho-binding site. The two positively charged fragments of BR25 forces the 
molecule to adopt a twisted conformation to maximize their interactions with the enzyme. While the 4-(dimeth-
ylamino)pyridinium fragment is characterized by a parallel π -cation interaction with Y333 and W420, respec-
tively, the 4-pyrrolidinopyridinium fragment is tethered by Y354, W420, F435 and Y440 (Fig. 4A). Note that the 
4-pyrrolidinopyridinium fragment establishes a parallel π-cation interaction with Y354 (Fig. 4A).
As expected, the benzyl-4-(dimethylamino)pyridinium fragment of compounds BR23 and BR31 superposes 
fairly well with an atomic shift of < 0.30 Å, supporting the high similarities between both compounds (Figure S1). 
In particular, the biphenyl group of compounds BR23 and BR31 shows optimal parallel hydrophobic stacking 
interactions with Tyr354, and the 4-(dimethylamino)pyridinium moiety interacts through a parallel π -cation 
interaction with Trp420. The second positively charged fragment is exposed to the solvent in these types of com-
pounds (Fig. 4C,D). A large RMSD of 7.6 Å between BR23 and BR25 also supports the large differences between 
these compounds in terms of their binding modes (Fig. 4E).
Both compounds were also computationally docked into PfCK showing very similar features as found for the 
human enzyme (Fig. 4F–H). Again, BR23 adopted the typical binding mode whereas BR25 adopted the unusual 
conformation mentioned above. This is not surprising since the identity at the Cho-binding site between HsCKα 1 
Inhibitor
HsCKα1 PfCK
Cho Etn ATP Cho Etn ATP
BR23 Mixed Ki, 0.114 ± 0.020 μ M α , 59 N.D.
Mixed Ki, 
 3.7 ± 0.8 μ M α , 0.73
Mixed Ki,  
38.2 ± 12.1 μ M α , 3.915
Competitive Ki, 
4.1 ± 0.2 μ M
Competitive Ki, 
116 ± 15 μ M
BR25 Mixed Ki, 0.100 ± 0.015 μ M α , 139 N.D.
Mixed Ki,  
4.1 ± 1.2 μ M α , 0.49
Mixed Ki,  
31.9 ± 5.5 μ M α , 2.025
Competitive Ki, 
4.0 ± 0.1 μ M
Mixed Ki,  
65.5 ± 5.7 μ M α , 2.37
Table 2.  Modes of inhibition and Ki values for inhibition of recombinant HsCKα1, PfCK and PfEK by 
BR23 and BR25. Means ± standard deviation (n = 3). N.D., not determined.
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Figure 4. Active site of HsCKα1 and PfCK in complex with compounds BR23, BR25, BR33 and BR31. 
(A,B) Close-up view of compounds BR25 (PDB entry 5FUT) and BR33 (PDB entry 4CG8) bound to HsCKα 1, 
respectively. (C,D) Close-up view of compounds BR23 (obtained by docking studies, see Methods) and  
BR31 (PDB entry 4CG9) bound to HsCKα 1, respectively. (E) Superposition of compound BR23 and BR25.  
(F,G) Close-up view of compounds BR25 and BR23 bound to PfCK (obtained by docking studies), respectively. 
(H) Superposition of bound compounds BR23 and BR25 within PfCK Cho-binding site. Residues as shown as 
yellow carbon sticks except for the partial conserved residue that is in orange carbon sticks. The electron density 
map from the FO− FC syntheses (grey) is contoured at 2.2 σ for BR25 (this density map is referred exclusively 
for BR25 in panel A). Note that we only report here the crystal structure of HsCKα 1 in complex with BR25. The 
others structures were published before (see PDB entries 4CG8 and 4CG9) or are obtained by docking studies 
(see Methods).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:33189 | DOI: 10.1038/srep33189
and PfCK is high with only a minor difference between two hydrophobic residues located in the adjacent binding 
site (Y256 and W238 in the human and the parasite enzyme, respectively; Fig. 4F,G).
A large RMSD of 7.0 Å between BR23 and BR25 (Fig. 4H) might explain the different type of inhibition mainly 
when ATP varies (Table 2). Furthermore, both compounds also show different types of inhibition depending 
whether choline or ethanolamine is the substrate (Table 2), which also goes in line with both alternative substrates 
(Cho and Etn) adopting different binding modes in the Cho binding site.
Discussion
This study set out to chemically validate either or both BR23 and BR25 as lead compounds that can effectively kill 
P. falciparum within red blood cells at low concentrations by preventing de novo synthesis of essential phospho-
lipids PE and/or PC, i.e. by inhibiting the Cho/Etn kinases of the Kennedy pathway (Fig. 5). Various eukaryotic 
kinases that initiate the Kennedy pathway have been shown to be able to phosphorylate both Cho and Etn12. 
However, it has been suggested that P. falciparum has separate enzymes catalysing phophorylation of Cho and 
Etn30,31, although these authors state that redundancy remains a possibility. Here we show that the HsCKα 1 is able 
to phosphorylate both Cho and Etn, with comparable kcats, despite a significantly preference (lower Km) for Cho 
in accordance with previous studies12. Likewise PfCK, despite its lower specific activity, is also able to phosphoryl-
ate both Cho and Etn with similar Kms to the human enzyme. The PfEK enzyme has a very low catalytic efficiency 
(~60 times less that PfCK) to phosphorylate Etn and showed no ability to phosphorylate Cho at all. This clearly 
shows that PfCK is potentially responsible for the phosphorylation of all the Cho and likely the major source of 
PE in the parasites for the Kennedy pathway leading to PC and PE, respectively. The overall pool of PC and PE 
would be also dependant upon the enzymes’ expression levels and possibly cellular location. However, both are 
expressed at similar levels according to PlasmoDB, and are located in the cytosol, suggesting that these two latter 
factors would not be the rate-limiting step for the synthesis of PC and PE, the later being essential for GPI biosyn-
thesis and maintaining the correct membrane composition, fluidity for numerous cellular processes and organelle 
function. Furthermore, it is obvious that the phosphoethanolamine N-methyltransferase acting upon PE is not 
the major source of PC as these levels remain relatively unchanged. Also the relative available concentration of 
Cho and Etn is crucial for the final effects of the inhibitors. In particular, intracellular Etn has been shown to be 
lower32, thus making Etn dependent enzymes more vulnerable to competitive inhibitors.
The potential inhibitory effect of BR23 and BR25 on both kinases was examined in detail by enzyme kinetics. 
Both BR23 and BR25 showed mixed inhibition of HsCKα 1 with respect to ATP and Cho, with Kis~4 uM, and 
Kis~100 nM respectively. The latter suggests that both compounds are competitive with respect to preventing the 
binding of the substrate (Cho/Etn). From the high sequence similarity between HsCKα 1 and PfCK especially 
within the active site, it is not surprising that BR23 and BR25 also showed mixed inhibition against PfCK for Cho 
(Kis ~35 uM), but compared to the human enzyme having less impact on Cho binding. However, both inhibitors 
were found to be competitive inhibitors of PfCK with respect to Etn with Kis of ~4 uM. This implies that the abso-
lute binding positions of the two alternative substrates (Cho and Etn) are different within the active site of PfCK. 
This is supported by the crystal structure of HsCKα 1 with BR25, where the compound adopts an unusual binding 
mode that induces the aperture of an adjacent binding site located at the back of the Cho-binding site. However, 
BR23 and related analogues with a short and rigid linker consisting of a biphenyl group were computationally 
predicted and experimentally proven to adopt a typical binding mode within the Cho-binding site of HsCKα 121,22.
When both compounds were computationally docked into PfCK, their respective binding modes were very 
similar to those found for the human enzyme where BR23 adopts the typical binding orientation and BR25 
adopted the unusual conformation mentioned above. Collectively, this data clearly shows that both compounds 
behave differently depending upon the enzyme and substrate identity, thus causing a more potent inhibition of 
PfCK when Etn is a substrate. A better understanding and exploitation of this adjacent binding mode near the 
Figure 5. Mechanism of action for the inhibitors BR23 and BR25. Cho, choline; PCho, phosphocholine; 
CDPCho, cytidine diphosphocholine; PC, phosphatidylcholine, Etn, ethanolamine; PEtn, phosphoethanolamine; 
CDPEtn, cytidine diphosphoethanolamine; PE, phosphatidylethanolamine; Ser, serine, PS, phosphatidylserine; 
CK, choline kinase; EK, ethanolamine kinase, PMT phosphoethanolamine-N-methyltransferase, CCT, choline-
phosphate cytidyltransferase; ECT, ethanolamine-phosphate cytidytransferase; CEPT, choline/ethanolamine 
phosphotransferase, PMT, phosphoethanolamine N-methyltransferase; PSS, phosphatidylserine synthase 
(CDP-DAG-dependent); PSSbe, phosphatidylserine synthase (via base exchange); PSD, phosphatidylserine 
descarboxylase.
www.nature.com/scientificreports/
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Cho binding site, may lead to greater potency and selectivity. While there is a Tyr (Y256) in the human enzyme, a 
Trp (W238) is present in the parasite enzyme (Fig. 4), which could be exploited to make selective compounds and 
could provide partially a plausible explanation for the selective nature of these compounds compared to mamma-
lian cells and their respective C/E kinases24.
Despite the fact that neither BR23 nor BR25 showed any inhibition towards PfEK, they did show significant 
inhibition of PfCK ethanolamine kinase activity, thus suggesting that they might affect the availability of PEtn to 
be used by the downstream enzymes of the Kennedy pathway for the de novo biosynthesis of PE, which ends up 
being lethal to the parasite. The observed differences between enzyme and parasite inhibition can be explained in 
a variety of ways: (a) the compounds may accumulate within the parasite, hence reaching a higher local concentra-
tion; and (b) the accumulative effect of inhibiting PE biosynthesis even at only 10–20% over a period of 24 hours 
might cause a significant decrease in the pool of PE that is lethal to the parasite. The latter may be especially true 
during periods of rapid cell growth/division when the demand on PE is high as will be the flux of PE biosynthesis.
Indeed quantitative lipidomic analysis of parasites treated with BR23 showed a significant reduction in the 
parasites PE species, while treatment with BR25 showed an almost complete loss of all of the endogenous PE spe-
cies. In stark contrast, treatments of BR23 or BR25 do not affect on the PC species significantly, highlighting again 
the differential inhibition of these compounds of PfCK in the presence of either Etn or Cho as substrate. This also 
highlights that both PfEK, which only phosphorylates Etn, and the possible decarboxylation of PS (Fig. 5), are 
unable to compensate for the lack of EK activity of the PfCK.
The reduced synthesis of PE in the parasites cause a number of detrimental issues that include the inability 
to synthesise mature GPI anchors and changes in the membrane composition (as it is a major lipid within the 
parasite). Inhibition of GPI synthesis disrupts the anchoring of essential cell-surface proteins to the membrane 
(i.e. MSP-1), as PE is the PEtn donor that links the proteins via their C-terminus to the third mannose of the 
GPI33. PE decrease also causes changes in membrane’s fluidity, which may also alter membrane potentials, leading 
to an impact on the functions within the mitochondria and potentially the apicoplast11.
In summary we have shown the following conclusions: (1) PfCK is responsible for producing the vast majority 
of the PEtn used by the parasite to make PE; (2) the type of inhibition by BR23 and BR25 on PfCK are influenced 
differentially by the presence of the alternative substrates, Etn or Cho; (3) the direct action of BR23 and BR25 on 
the parasites is to inhibit the formation of PEtn directly reducing the de novo biosynthesis of PE via the Kennedy 
pathway, which is ultimately lethal to the parasite; and (4) BR23 and BR25 are lead compounds with potent and 
selective nanomolar antiplasmodium activity that have been chemically validated against PfCK.
Materials and Methods
Cloning and purification of HsCKα1, PfCK and PfEK. Details about cloning and purification of human 
CKα 1 and PfCK have been previously reported20,23.
The DNA sequence encoding amino acid residues 2–420 of PfEK, defined as pfek, was made synthetically and 
codon optimized by GenScript to be expressed in E. coli. pfek was amplified using the forward primer,
5′ -CGGAATTCCATATGGAATACCAACTGCGTGAAATTG-3′ containing a NdeI site (italic), and the 
reverse primer
5′ -CGGAATTCGTCGACTCACAGTTTGCTGCGGAATTTCAC-3′ containing a SalI site (italic) and a stop 
codon (underlined). Subsequently the PCR product was digested with NdeI and SalI and cloned into a modified 
pET15b vector containing a histidine tag and a PreScission protease (PP) cleavage site, resulting in the expression 
plasmid pET15bPP-pfek. The plasmid was verified by sequencing.
pET15bPP-pfek was transformed into BL21 DE3 (star) cells grown in 2XYT medium with 100 μ g/ml of ampi-
cillin. Cells were grown at 37 °C until reaching an OD of 0.6 at 600 nm, after which the expression of the protein 
was induced overnight by 1 mM IPTG at 18 °C and 180 rpm.
The cells were harvested by centrifugation at 3480 g for 30 min and suspended in buffer A (20 mM phosphate, 
500 mM NaCl, 10 mM imidazole, pH 7.4), containing lysozyme (1 mg/ml)), DNAse (0.1 mg/ml) and a cocktail 
of protease inhibitors (0.2 mM PMSF, 10 mM benzamidine and 0.5 mM leupeptin). The cells were disrupted by 
sonication and centrifuged at 19500 g at 4 °C for 30 minutes.
The supernatants were applied onto a 1 × 5 ml cobalt HP column (GE Healthcare) previously equilibrated 
with buffer A. The column was washed with buffer A and the fusion protein was eluted with buffer A containing 
500 mM imidazole. The fusion protein was dialysed with buffer B (25 mM Tris/HCl, 150 mM NaCl pH 7.5) and 
subsequently was cleaved overnight with PP (GE Healthcare) at 4 °C. The PP was removed by a GSTrap column 
and the unbound untagged protein was applied onto a 1 × 5 ml cobalt HP column (GE Healthcare) previously 
equilibrated with buffer B. The unbound protein was further purified by size exclusion chromatography using a 
Superdex 75 XK26/60 column previously equilibrated with two volumes of buffer B. The eluted peaks were con-
centrated and used for biophysical experiments. The purity of the recombinant PfEK was assessed by SDS-PAGE. 
PfEK concentrations were determined spectrophotometrically using the extinction coefficient at 280 nm of 
1.129 mg ml−1 cm−1. Finally the protein was stored in buffer B at − 80 °C.
P. falciparum culture and microscopy. P. falciparum 3D7 was cultured according to standard methods34, 
and a 6 hours window was achieved by a combination of Percoll and sorbitol synchronizations35. Briefly, schizonts 
and late trophozoites were isolated from earlier stages according to their density by centrifugation on a continu-
ous gradient of 60% Percoll. The resulting schizonts were allowed to invade uninfected red blood cells for 6 hours 
and newly infected red blood cells were subjected to a 5% sorbitol treatment for 10 minutes at 37 °C. Parasitemia 
was adjusted to ≈ 0.5% and either BR23 or BR25 inhibitors were inoculated at their EC90s) after 6 additional hours 
of incubation (i.e. 6–12 hours post-invasion). Thin blood smears were Giemsa stained every 6 hours until an 
entire intraerythrocytic cycle was completed.
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P. falciparum lipid extraction. P. falciparum 3D7 were cultured with BR23 or BR25 inhibitors at their 
EC90s for 3h after sorbitol synchronization. After washing, P. falciparum trophozoites were cultured for 18h with-
out inhibitors, collected, treated with saponin to release the parasites from the red blood cells, and washed twice 
with PBS prior to Bligh & Dyer lipid extraction36. Briefly, 5 × 108 parasite cells were dissolved in 375 μ l 1:2 (v/v) 
chloroform:methanol and vigorously vortexed for 15 min. 125 μ l of chloroform were added and 500 pmols of 
1,2-dimyristoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine were 
included in each sample as internal controls. 125 μ l of water were added to the sample, vortexed and centrifuged 
at × 1000 g (RT) for 5 min to make the sample biphasic. Lower organic phase was collected and upper (aqueous) 
phase was re-extracted twice with 125 μ ls of chloroform. Lipid extracts were pooled, dried under nitrogen and 
stored at 4 °C for ESI-MS/MS analysis.
Assays for CK and EK enzyme activites. A continuous spectrophotometric 96-well plate assay was estab-
lished for CK and EK activity based on an assay described37. The standard assay reaction contained, in a final 
volume of 100 μ l: 50 mM MOPS, pH 7.8, 150 mM KCl, 6 mM MgCl2, 1 mM PEP, 1 mM NADH, 6 U/mL pyruvate 
kinase, 9 U/mL lactate dehydrogenase, 4 mM Cho or Etn, 2 mM ATP (for PfEK) or 4 mM ATP (for CKs) and 
0.1–50 μ g enzyme. The reaction was initiated by addition of enzyme or substrate, as appropriate, and the rate of 
reaction was monitored by following the decrease in absorbance at 341 nm for 10 min at room temperature using 
a Thermo Multiska spectrophotometer. Experiments were carried out to ensure that coupling enzymes were not 
rate-limiting under any of the conditions used and control experiments lacking substrates and/or enzyme were 
carried out to correct for any background rate.
Kinetic analyses. One substrate was held constant at the concentration specified above while the second 
substrate was varied. Any ATPase activity was controlled for and subtracted from the rates (PfEK only). Curves 
were plotted and Km and Vmax values estimated using Grafit 5 (Erithacus Software Ltd).
IC50 determinations. The enzyme was pre-incubated for 5 min with varying concentrations of inhibitor 
prior to reaction being started by addition of 0.5 mM each substrate. The IC50 values were estimated using Grafit 
5 (Erithacus Software Ltd).
Ki determinations. Activity was measured at 3–4 different concentrations of inhibitor and a fixed concentra-
tion of one substrate (as specified in the standard assay) while the second substrate was varied. GraphPad Prism 
6 (GraphPad Software Inc.) was used to fit data to different inhibition models with the best fit being determined 
by Aike’s Informative Criteria. Kis were estimated from the best-fit model and results were reinforced by linear 
re-plots of the data (Lineweaver Burke, Dixon, s/v against I)38.
Electrospray-mass spectrometry analysis. Lipid extracts, were dissolved in 15 μ l of choloroform:meth-
anol (1:2) and 15 μ l of acetonitrile:iso-propanol:water (6:7:2) and analysed with a Absceix 4000 QTrap, a tri-
ple quadrupole mass spectrometer equipped with a nanoelectrospray source. Samples were delivered using a 
Nanomate interface in direct infusion mode (~125 nl/min). The lipid extracts were analysed in both positive and 
negative ion modes using a capillary voltage of 1.25 kV. MS/MS scanning (daughter, precursor and neutral loss 
scans) were performed using nitrogen as the collision gas with collision energies between 35–90 V. Each spectrum 
encompasses at least 50 repetitive scans. Tandem mass spectra (MS/MS) were obtained with collision energies 
between 35–90 V. Assignment of phospholipid and neutral lipid species is based upon a combination of survey, 
daughter, precursor and neutral loss scans, as well previous assignments25,39. The identity of phospholipid peaks 
was verified using the LIPID MAPS: Nature Lipidomics Gateway (www.lipidmaps.org).
Docking studies. Whereas Maestro 9.3 software40 has been used for docking studies, Pymol41 has been used 
for preparing the figures that represent the obtained poses. PDB entries 4CG922 and 3FI8 have been selected as 
templates for the docking studies of compounds BR23 and BR25 in HsCKα 1 and PfCK. The PDB entry 4CG9 has 
been used for predicting the docking pose of compound BR23 in HsCKα 1 because it contains compound BR3122, 
which is an analog of compound BR23.
In a first step, all the proteins were aligned using the Protein Structure Alignment tool included into Maestro 
9.3. Then, Protein Preparation Wizard module42 was used for preparing the protein structures. A pre-process was 
made adding hydrogen atoms and assigning bond orders. The PROPKA script43,44 was used to assign the correct 
tautomeric and protonation state of the amino acids at pH 7.0 ± 1.0 for optimizing H-bonds networks. Finally, an 
initial restrained minimization using the OPLS2500 force field and a convergence RMSD of 0.3 Å for heavy atoms 
were performed in order to optimize the protein and to assign the partial atomic charge to each atom. A potential 
map for PDB entries 4CG9 (HsCKα 1) and 3FI8 (PfCK) were generated using the Shrödinger Glide module45. 
Compounds BR31 and BR25 were imported into PfCK Cho-binding site as a reference for the Grid generation, 
being the Grid box centered in these molecules and defined with a high volume (25 Å) to allow the insertion 
of compounds BR23 and BR25. Once the 3D structures were prepared for each compound (whereas BR23 was 
obtained after adding the 4-pyrrolidinopyridine moiety to compound BR31, we used the BR25 structure visual-
ized in the crystal structure), each molecule was optimized by means of the MacroModel module using the OPLS 
2500 force field and a convergence gradient of 0.05 Å. After minimization, the LigPrep module46 was used for pre-
paring the ligands for docking studies generating all possible conformers and protonation states at pH = 7.0 ± 1.0.
Finally, Glide was used to flexibly dock compounds BR23 and BR25 into the active site of both proteins (4CG9 
and 3FI8 pdb codes) with extra precision, and BR25 into PfCK binding pocket (3FI8) in the same conditions.
Tryptophan fluorescence. Compounds BR23 and BR25 were prepared in 100% DMSO. The Kds for com-
pounds BR23 and BR25 against HsCKα 1 and PfCK were measured by monitoring the quenching of tryptophan 
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fluorescence. All experiments were carried out in a Cary Eclipse spectrofluorometer at 25 °C with the enzymes 
at 1 μ M, and concentrations of compounds varying from 0.05 to 8 μ M for HsCKα 1, and from 0.05 to 16 μ M for 
PfCK in 25 mM Tris, 150 mM NaCl, pH 7.5. Fluorescence emission spectra were recorded in the 300–400 nm 
range with an excitation wavelength of 280 nm, with slit width of 5 nm. Controls were determined by incubating 
the enzymes with equivalent amounts of DMSO. As indicated previously, data analysis was performed in Prism 
(GraphPad software) considering a model with a single binding site (Eq. 1), where F0 is the intrinsic fluorescence 
of the enzyme in the absence of quencher (Q), F1 is the observed fluorescence at a given quencher concentration, 
fa is the fractional degree of fluorescence, and Kd is the dissociation constant.
=
+
F Q
Kd Q
1 [ ]
[ ] (1)
Protein crystallization. HsCKα 1 at 20 mg/ml in buffer 25 mM Tris/HCl, 150 mM NaCl pH 7.5 was prein-
cubated at room temperature with 12 mM of compound BR25 (DMSO is at 5% final concentration in the mix). 
The sitting-drop vapour diffusion method47 was used to produce crystals by mixing 0.5 μ l of the protein solu-
tion and an equal volume of mother liquor (20% PEG 5000 MME and 0.2 M KSCN). Tetragonal crystals (space 
group P43212) grew within 2–4 days and then were soaked for one day with 20 mM compound BR25 (the final 
concentration of DMSO during the soaking was ~5%). The crystals used in this study were cryoprotected in the 
previously stated mother liquor solution containing an additional 20% ethylenglycol and frozen in a nitrogen gas 
stream cooled to 100 K.
Structure determination and refinement. Diffraction data of the binary complex was collected at 
XALOC (ALBA, Barcelona). The data was processed and scaled using the XDS package48 and CCP4 software49. 
The structure of the binary complex was solved by molecular replacement (MOLREP)50 using PDB entry 4CG922 
as a template. Initial phases were further improved by cycles of manual model building in Coot51 and restrained 
refinement with REFMAC552. Finally, additional cycles of model building in Coot with TLS refinement in 
PHENIX53 were performed. The final model was validated with PROCHECK54) and relevant statistics are given 
in S3 Table. The topology for BR25 was generated with PRODRG55. Coordinates and structure factors have been 
deposited in the Worldwide Protein Data Bank (wwPDB; see S3 Table for the pdb code).
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